Tislelizumab with Azacitidine in the Treatment of R/R AML

NCT06586099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped withdrawn

Conditions

Refractory AML
Relapsed Adult AML

Interventions

DRUG: Aza, tislelizumab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China